RxDoctor Payments Data

Rebecca Agnew

Nurse Practitioner · Pittsburgh, PANPI 1881616001

Payments from drug & device makers

$5,211in general payments, 2019–2025

Across 68 payments — averaging $76.64 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$1K
  • Vifor Pharma, Inc.$852
  • Travere Therapeutics, Inc.$583
  • Fresenius USA Marketing, Inc.$573
  • AstraZeneca$541
  • Ardelyx, Inc.$296
  • plus $953 from 9 others

What the payments were for

  • Food & beverage$5,211100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$5,211 in reported general payments places this provider in the 95th percentile of 4,059 nurse practitioner providers in Pennsylvania.

See all nurse practitioner providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$8,949
Medicare patients
27
Services billed
46

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
AuryxiaFerric Citrate38$51,658
ClinolipidFat Emulsion/Olive/Soy/Phospho184$46,326
ProsolParenteral Amino Acid 20% No.166$29,913
VeltassaPatiromer Calcium Sorbitex20$17,757
Sevelamer Carbonate58$6,035
Calcium Acetate62$2,715
Clonidine12$1,011
Minoxidil34$424
Albuterol Sulfate HfaAlbuterol Sulfate23$361
Metoprolol Succinate29$310
Amlodipine Besylate39$192
Carvedilol18$171
Losartan Potassium31$159
Valsartan11$121
Atorvastatin Calcium13$113

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Akebia Therapeutics IncAuryxia$186$51,65838 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 4,059 nurse practitioner providers in Pennsylvania.

Other nurse practitioner in Pittsburgh

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →